

Ebola control: effect of asymptomatic infection and acquired immunity

Evidence suggests that many Ebola infections are asymptomatic,^{1,2} a factor overlooked by recent outbreak summaries and projections.³ Particularly, results from one post-Ebola outbreak serosurvey¹ showed that 71% of seropositive individuals did not have the disease; another study² reported that 46% of asymptomatic close contacts of patients with Ebola were seropositive. Although asymptomatic infections are unlikely to be infectious,³ they might confer protective immunity and thus have important epidemiological consequences.

Although a forceful response is needed, forecasts that ignore naturally acquired immunity from asymptomatic infections overestimate incidence late in epidemics. We illustrate this point by comparing the projections of two simple models based on the Ebola epidemic in Liberia, a model that does not account for asymptomatic infections, and another that assumes 50% of infections are asymptomatic and induce protective immunity. In both models, the basic reproduction number (R_0) is identical and based on published estimates.³ The figure shows the projected cumulative incidence through time. Although the initial outbreaks are almost identical, by Jan 10, the model without asymptomatic infections projects 50% more cumulative symptomatic cases than the model that accounts for asymptomatic infection. This difference arises because asymptomatic infection contributes to herd immunity and thereby dampens epidemic spread.

Widespread asymptomatic immunity would likewise have implications for Ebola control measures and should be considered when planning intervention strategies. For instance, should a

safe and effective vaccine become available, the vaccination coverage needed for elimination will depend on pre-existing immunity in the population (appendix). Immunity resulting from asymptomatic infections should reduce the intervention effort needed to interrupt transmission but might also complicate the design and interpretation of vaccine trials. Trials and interventions are likely to target exactly those high-risk populations most likely to have been asymptotically immunised. Thus, for assessment of vaccines and other countermeasures, baseline serum should be collected to improve both estimates of intervention effectiveness and our understanding of asymptomatic immunity. Additionally, assessment of intervention measures should account for the contribution of asymptomatic immunity in curbing epidemic spread.

Asymptomatic infection could also potentially be directly harnessed to mitigate transmission. If individuals who have cleared asymptomatic infections could be identified reliably, and if they are indeed immune to symptomatic re-infection, they could potentially be recruited to serve as caregivers or to undertake other high-risk disease control tasks, providing a buffer akin to that of ring vaccination. Recruitment of such individuals might be preferable to enlistment of survivors of symptomatic Ebola disease because survivors might experience psychological trauma or stigmatisation and be fewer in number—in view of the asymptomatic proportions suggested in previous studies^{1,2} and the low survival rate of symptomatic cases.³ Health-care workers with natural immunity acquired from asymptomatic infection, if identified, could be allocated to care for acutely ill and infectious patients, minimising disease spread to susceptible health-care workers.

The conclusions above depend on whether asymptomatic infections are common, and protective against future infection. Further, strategies to leverage protective immunity will depend on the development and validation of assays that can reliably identify individuals who are effectively protected against re-infection. Previous studies have identified many asymptomatic infections using IgM and IgG antibody assays and PCR,^{1,2} which, although indicative of infection, do not necessarily imply protective immunity.⁴ Evidence for long-term protective immunity reported in (symptomatic) Ebola survivors is suggestive,⁴ but the extent of protective immunity after asymptomatic infection and the identification of serological markers for protective immunity can only be definitively addressed in settings with ongoing transmission risk. As has been proposed for vaccination,⁵ the epidemic therefore provides a unique opportunity to investigate asymptotically acquired protective immunity to Ebola virus. Although resources are scarce, now is the time for interventions protecting people at risk of contracting Ebola (ie, health-care workers and household caregivers) to incorporate



Published Online
October 14, 2014
[http://dx.doi.org/10.1016/S0140-6736\(14\)61839-0](http://dx.doi.org/10.1016/S0140-6736(14)61839-0)

See Online for appendix

For the Ebola code repository
see <http://ebola.ici3d.org>




Figure: Effects of immunising asymptomatic infections on Liberia outbreak projections

Projected cumulative incidence including and excluding asymptomatic infection. If 50% of infections are asymptomatic, then models overlooking asymptomatic infection will overestimate disease incidence later in the epidemic, as individuals who were asymptotically infected become immune and contribute to herd immunity. By Jan 10, 2015 (red vertical line) models ignoring asymptomatic immunity overestimate cumulative incidence by 50% (red). The code for models and calculations are from the Ebola code repository.

serological assessments to ascertain asymptomatic infections—feasible with even introduced cases such as recently occurred in Dallas, Texas—and immunological correlates of protection—feasible only in settings with ongoing transmission.

A more direct investigation of asymptotically acquired immunity might be possible by leveraging proposed trials to assess the efficacy of blood transfusions from Ebola survivors.⁶ During the 1995 outbreak in DR Congo, a study reported increased survival rates in transfusion recipients but was potentially confounded by the superior supportive care afforded to the treated patients.⁷ Burnouf and colleagues⁶ have advocated for randomised controlled clinical trials comparing the treatment efficacy of transfusions from survivors with those from control donors. By including a third study group in which patients receive transfusions from asymptomatic seropositive individuals, this design could simultaneously assess the therapeutic value of these transfusions from asymptomatic individuals, and indicate whether such individuals have protective immunity.

We propose that launching of an immediate investigation of asymptomatic immunity, by coupling serological testing to ongoing intervention efforts in west Africa, is warranted and feasible, and might ultimately save lives.

We thank David Champredon, Stephanie Cinkovich, and Spencer Fox for assistance with reviewing the literature, and Carl Pearson for helpful discussions. We acknowledge support from NIGMS, MIDAS, RAPIDD, NIH, CIHR, and NSERC.

We declare no competing interests.

**Steve E Bellan, Juliet R C Pulliam, Jonathan Dushoff, Lauren Ancel Meyers*
steve.bellan@gmail.com

Center for Computational Biology and Bioinformatics (SEB) and Department of Integrative Biology (LAM), The University of Texas at Austin, Austin, TX 78712, USA; Department of Biology and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA (JRCP); Fogarty International Center, National Institutes of Health, Bethesda, MD, USA (JRCP); Department of Biology and Institute of

Infectious Disease Research, McMaster University, Hamilton, ON, Canada (JD); and Santa Fe Institute, Santa Fe, NM, USA (LAM)

- 1 Heffernan RT, Pambo B, Hatchett RJ, Leman PA, Swanepoel R, Ryder RW. Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 1997. *J Infect Dis* 2005; **191**: 964–68.
- 2 Leroy E, Baize S, Volchkov V. Human asymptomatic Ebola infection and strong inflammatory response. *Lancet* 2000; **355**: 2210–15.
- 3 WHO Ebola Response Team. Ebola virus disease in west Africa—the first 9 months of the epidemic and forward projections. *N Engl J Med* 2014; published online Sept 23. DOI:10.1056/NEJMoa1411100.
- 4 Wong G, Kobinger GP, Qiu X. Characterization of host immune responses in Ebola virus infections. *Expert Rev Clin Immunol* 2014; **10**: 781–90.
- 5 Galvani AP, Ndeffo-Mbah ML, Wenzel N, Childs JE. Ebola vaccination: if not now, when? *Ann Intern Med* 2014; published online Aug 21. DOI:10.7326/M14-1904.
- 6 Burnouf T, Emmanuel J, Mbanya D, et al. Ebola: a call for blood transfusion strategy in sub-Saharan Africa. *Lancet* 2014; published online Sept 29. [http://dx.doi.org/10.1016/S0140-6736\(14\)61693-7](http://dx.doi.org/10.1016/S0140-6736(14)61693-7).
- 7 Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. *J Infect Dis* 1999; **179**: 518–23.